The role of prostaglandin analogues and minimally invasive glaucoma surgery in long-term disease control: a case based-review Opis przypadku

##plugins.themes.bootstrap3.article.main##

Jakub Gajdecki
Anna Michalska
Paweł Stala

Abstrakt

Purpose: To present a case of long-term primary open angle glaucoma management and discuss various therapeutical approaches.


Case: During a 11-year long follow-up period of a 58-year-old woman with primary open angle glaucoma we observed signs of disease progression despite intraocular pressure within normal range and triple anti-glaucomatous therapy. Proper switch of therapeutic agent together with implementation of minimally invasive glaucoma surgery helped to maintain a stable condition.


Conclusion: Regular monitoring of glaucoma patients is crucial for recognition of early signs of progression in order to properly amend the pharmacotherapy or implement adequate surgical treatment.

##plugins.generic.usageStats.downloads##

##plugins.generic.usageStats.noStats##

##plugins.themes.bootstrap3.article.details##

Dział
Chirurgia i laseroterapia

Bibliografia

1. Leske M, Heijl A, Hussein M et al. Early Manifest Glaucoma Trial Group. Factors for glaucoma progression and the effect of treatment: the early manifest glaucoma trial. Arch Ophthalmol. 2003; 121(1): 48-56.
2. Mills R, Budenz D, Lee P et al. Categorizing the stage of glaucoma from pre-diagnosis to end-stage disease. Am J Ophthalmol. 2006; 141(1): 24-30.
3. Coleman A, Miglior S. Risk factors for glaucoma onset and progression. Surv Ophthalmol. 2008; 53(Suppl. 1): S3-10.
4. Jiang X, Varma R, Wu S et al.; Los Angeles Latino Eye Study Group. Baseline risk factors that predict the development of open-angle glaucoma in a population: the Los Angeles Latino Eye Study. Ophthalmology. 2012; 119(11): 2245-53.
5. Baskaran M, Foo R, Cheng C et al. The Prevalence and Types of Glaucoma in an Urban Chinese Population: The Singapore Chinese Eye Study. JAMA Ophthalmol. 2015; 133(8): 874-80.
6. Jammal A, Berchuck S, Thompson A et al. The Effect of Age on Increasing Susceptibility to Retinal Nerve Fiber Layer Loss in Glaucoma. Invest Ophthalmol Vis Sci. 2020; 61(13): 8.
7. Hollows F, Graham P. Intra-ocular pressure, glaucoma, and glaucoma suspects in a defined population. Br J Ophthalmol. 1966; 50(10): 570-86.
8. Bankes J, Perkins E, Tsolakis S et al. Bedford glaucoma survey. Br Med J. 1968; 1(5595): 791-6.
9. Bengtsson B. The prevalence of glaucoma. Br J Ophthalmol. 1981; 65(1): 46-9.
10. Mitchell P, Smith W, Attebo K et al. Prevalence of open-angle glaucoma in Australia. The Blue Mountains Eye Study. Ophthalmology. 1996; 103(10): 1661-9.
11. Giuffrè G, Giammanco R, Dardanoni G et al. Prevalence of glaucoma and distribution of intraocular pressure in a population. The Casteldaccia Eye Study. Acta Ophthalmol Scand. 1995; 73(3): 222-5.
12. Kahn H, Leibowitz H, Ganley J et al.; The Framingham Eye Study. I. Outline and major prevalence findings. Am J Epidemiol. 1977; 106(1): 17-32.
13. Tielsch J, Sommer A, Katz J et al. Racial variation in the prevalence of primary open angle glaucoma. JAMA. 1991; 266(3): 369-74.
14. Cedrone C, Culasso F, Cesareo M et al. Prevalence of glaucoma in Ponza, Italy: a comparison with other studies. Ophthalmic Epidemiol. 1997; 4(2): 59-72.
15. Fung A, Reid S, Jones M et al. Meta-analysis of randomised controlled trials comparing latanoprost with brimonidine in the treatment of open-angle glaucoma, ocular hypertension or normal-tension glaucoma. Br J Ophthalmol. 2007; 91(1): 62-8.
16. Kampik A, Arias-Puente A, O’Brart D et al.; European Latanoprost Study Group. Intraocular pressure-lowering effects of latanoprost and brimonidine therapy in patients with open-angle glaucoma or ocular hypertension: a randomized observer masked multicenter study. J Glaucoma. 2002; 11(2): 90-6.
17. Camras C, Sheu W; United States Latanoprost-Brimonidine Study Group. Latanoprost or brimonidine as treatment for elevated intraocular pressure: multicenter trial in the United States. J Glaucoma. 2005; 14(2): 161-7.
18. Alm A. Latanoprost in the treatment of glaucoma. Clin Ophthalmol. 2014; 8: 1967-85.
19. Francis BA, Winarko J. Ab interno Schlemm’s canal surgery: trabectome and i-stent. Dev Ophthalmol. 2012; 50: 125-36.
20. Le K, Saheb H. iStent trabecular micro-bypass stent for open-angle glaucoma. Clin Ophthalmol. 2014; 8: 1937-45.
21. Guedes RAP, Gravina DM, Lake JC et al. Intermediate Results of iStent or iStent inject Implantation Combined with Cataract Surgery in a Real-World Setting: A Longitudinal Retrospective Study. Ophthalmol Ther. 2019; 8(1): 87-100.
22. Jea SY, Francis BA, Vakili G et al. Ab interno trabeculectomy versus trabeculectomy for open-angle glaucoma. Ophthalmology. 2012; 119(1): 36-42.
23. Pantcheva MB, Kahook MY. Ab interno trabeculectomy. Middle East Afr J Ophthalmol. 2010; 17(4): 287-9.
24. Al Yousef Y, Strzalkowska A, Hillenkamp J et al. Comparison of a second-generation trabecular bypass (iStent inject) to ab interno trabeculectomy (Trabectome) by exact matching. Graefes Arch Clin Exp Ophthalmol. 2020; 258(12): 2775-80.